TELA Bio, Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 8, 2026, TELA Bio, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstanding shares of the Company’s common stock, par value $0.001 per share. The Special Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Special Meeting, which are described in detail in the Company’s Proxy Statement. As previously reported by the Company on Current Form 8-K, on October 5, 2026, the Company received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). As a result, the Company does not intend to effect the reverse stock split at this time. (a) Proposal 1 - Approval of an amendment to the Company’s Certificate of Incorporation to combine outstanding shares of the Company’s common stock into a lesser number of outstanding shares by a ratio of not less than one-for-five and not more than one-for-fifteen, with the exact ratio to be set within this range by the Board, in its sole discretion. The amendment to the Company’s Certificate of Incorporation was approved, as follows: Votes For Votes Against Abstentions Broker Non-Votes ──────────────────────────────────────────────────────────────────────── 30,515,571 80,512 1,737,011 0 (b) Proposal 2 - Approval of an adjournment of the Special Meeting, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes in favor of Proposal 1. The adjournment was approved, as follows: Votes For Votes Against Abstentions Broker Non-Votes ──────────────────────────────────────────────────────────────────────── 30,757,679 123,860 1,451,555 0